News – Page 1194 – Endpoints News

One of Shire’s top pipeline prospects fails a PhII study among preemies

10 years ago

Bruised but standing, Syros braves its way through a $50M IPO

10 years ago

Novartis shoots for early OK of a ‘breakthrough’ blood cancer drug after reversing organ damage in trial

10 years ago

The biotech IPO feast flags as investors lose their appetite for R&D risk

10 years ago

What PDUFA date? Clovis shares surge as PARPs get trendy on Wall Street

10 years ago

Neoantigens beckon Merck into a $200M cancer collaboration with Moderna

10 years ago

Galena implodes as trial monitors call a halt to a failed PhIII cancer study

10 years ago

Tesaro rockets up after PARP inhibitor aces PhIII study and R&D rivalry intensifies

10 years ago

Esperion tanks on warning that the road to an FDA decision could be much, much longer than they thought

10 years ago

Two flops in two weeks for Marinus Pharmaceuticals' ganaxolone

10 years ago

Troubled Infinity axes 100 staffers, shutters trials and rewards top execs after AbbVie walks away from deal

10 years ago

In latest setback for stem cell sector, Celyad fails PhIII— and the biotech claims a victory

10 years ago

Novartis inks a $2.5B bispecific cancer drug development alliance with Xencor

10 years ago

Regulus craters after FDA slaps a hold on hep C RNA drug following 2nd case of jaundice

10 years ago

Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

10 years ago

Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up

10 years ago

GW Pharma’s rally rolls on as cannabinoid drug scores again in PhIII Epidiolex anti-convulsive study

10 years ago

The Zerhouni rule: “Every company that acquires a platform company kills it.”

10 years ago

Scoring the 5 top phase III drugs in the global pipeline

10 years ago

IPO bound? CRISPR Therapeutics ups B round to a cool $140M

10 years ago

Medivation to Sanofi (in translation): You don't know beans about cancer drug development(!)

10 years ago

What’s ahead for UK biotechs in the wake of Brexit? It's not a pretty picture

10 years ago

These 300(+) Biotech Twitter citizens are the quickest to tweet news

10 years ago

VC giant NEA backs an upstart’s plan to tackle neurodegeneration

10 years ago

First page Previous page 1191 1192 119311941195 Next page Last page